Kura Oncology, Inc. financial data

Symbol
KURA on Nasdaq
Industry
Pharmaceutical Preparations
Location
12730 High Bluff Drive, Suite 400, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
ZETA ACQUISITION CORP III (to 3/10/2015)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.37K % -28.4%
Debt-to-equity 11.4 % +33.6%
Return On Equity -44.1 % -31.5%
Return On Assets -39.6 % -28.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77.8M shares +4.7%
Common Stock, Shares, Outstanding 77.7M shares +4.71%
Entity Public Float 777M USD -35.3%
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 87M shares +12.6%
Weighted Average Number of Shares Outstanding, Diluted 87M shares +12.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 150M USD +42.6%
General and Administrative Expense 67.3M USD +37.8%
Nonoperating Income (Expense) 20M USD +77.5%
Net Income (Loss) Attributable to Parent -198M USD -38.2%
Earnings Per Share, Basic -2.36 USD/shares -16.8%
Earnings Per Share, Diluted -2.36 USD/shares -16.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49.5M USD +72.2%
Assets, Current 463M USD +0.71%
Property, Plant and Equipment, Net 1.32M USD -36.1%
Operating Lease, Right-of-Use Asset 6.1M USD -16.2%
Other Assets, Noncurrent 8.23M USD +82.3%
Assets 479M USD +1.07%
Accounts Payable, Current 3.01M USD +70.6%
Employee-related Liabilities, Current 12.5M USD +37.6%
Liabilities, Current 40.4M USD +46.7%
Operating Lease, Liability, Noncurrent 5.47M USD -15.3%
Other Liabilities, Noncurrent 1.47M USD +159%
Liabilities 55.1M USD +25.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.12M USD
Retained Earnings (Accumulated Deficit) -876M USD -29.1%
Stockholders' Equity Attributable to Parent 424M USD -1.43%
Liabilities and Equity 479M USD +1.07%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -48.8M USD -36.2%
Net Cash Provided by (Used in) Financing Activities 303K USD +284%
Net Cash Provided by (Used in) Investing Activities -95.3M USD -957%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 77.7M shares +4.71%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.19M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 49.5M USD +72.2%
Deferred Tax Assets, Valuation Allowance 224M USD +27.1%
Deferred Tax Assets, Gross 226M USD +27.4%
Operating Lease, Liability 7.16M USD -12%
Depreciation 234K USD +13.6%
Payments to Acquire Property, Plant, and Equipment 84K USD +133%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -193M USD -40.7%
Lessee, Operating Lease, Liability, to be Paid 10.1M USD -14.7%
Property, Plant and Equipment, Gross 4.39M USD +2.1%
Operating Lease, Liability, Current 1.69M USD +0.54%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.34M USD -31.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.96M USD +27.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +9.71%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.93M USD -20.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.37M USD +2.01%
Deferred Tax Assets, Operating Loss Carryforwards 144M USD +14.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 10.1M USD +56%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.4M USD +1.97%
Operating Lease, Payments 500K USD -16.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.34M USD -28.6%
Interest Expense 1.6M USD +4.91%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%